Immix Biopharma, Inc. (NASDAQ:IMMX) Sees Significant Increase in Short Interest

Immix Biopharma, Inc. (NASDAQ:IMMX) saw a large growth in short interest in the month of January. As of January 30th, there was short interest totaling 2,990,326 shares, a growth of 31.9% from the January 15th total of 2,266,456 shares. Currently, 12.7% of the shares of the stock are sold short. Based on an average trading volume of 961,464 shares, the short-interest ratio is presently 3.1 days. Based on an average trading volume of 961,464 shares, the short-interest ratio is presently 3.1 days. Currently, 12.7% of the shares of the stock are sold short.

Immix Biopharma Trading Up 10.8%

NASDAQ IMMX opened at $8.12 on Wednesday. The firm has a market cap of $430.04 million, a price-to-earnings ratio of -10.55 and a beta of 0.31. The company has a 50 day moving average of $5.80 and a 200-day moving average of $3.95. Immix Biopharma has a 1-year low of $1.34 and a 1-year high of $8.25.

Institutional Trading of Immix Biopharma

Large investors have recently made changes to their positions in the business. United Capital Financial Advisors LLC acquired a new position in Immix Biopharma during the 3rd quarter worth $148,000. Susquehanna International Group LLP raised its position in shares of Immix Biopharma by 78.8% during the third quarter. Susquehanna International Group LLP now owns 90,858 shares of the company’s stock worth $190,000 after acquiring an additional 40,032 shares during the last quarter. Citadel Advisors LLC acquired a new position in shares of Immix Biopharma during the third quarter valued at $188,000. Imprint Wealth LLC bought a new position in Immix Biopharma in the third quarter valued at about $141,000. Finally, TritonPoint Partners LLC acquired a new stake in Immix Biopharma in the fourth quarter worth about $128,000. Institutional investors own 11.26% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on IMMX. Weiss Ratings reissued a “sell (d-)” rating on shares of Immix Biopharma in a research note on Thursday, January 22nd. Mizuho started coverage on Immix Biopharma in a research note on Monday, February 9th. They issued an “outperform” rating and a $14.00 price objective on the stock. Finally, Wall Street Zen cut Immix Biopharma from a “hold” rating to a “sell” rating in a report on Saturday. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $11.00.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.